Head and neck squamous cell carcinoma

December 20, 2022

Trial Spotlight: Robert Ferris on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
January 26, 2022

Now Enrolling: EA3202 for Head and Neck Squamous Cell Carcinoma

This phase II/III study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
August 17, 2021

Trial Spotlight: Dan Zandberg on the EA3191 Study for Head and Neck Squamous Cell Carcinoma

This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy